Literature DB >> 27660198

PD-1/PD-L and autoimmunity: A growing relationship.

Mohammad Reza Zamani1, Saeed Aslani2, Arash Salmaninejad3, Mohammad Reza Javan4, Nima Rezaei5.   

Abstract

Programmed death 1 (PD-1) and its ligands, namely PD-L1 and PD-L2, are one of the key factors responsible for inhibitory T cell signaling, mediating the mechanisms of tolerance and providing immune homeostasis. Mounting evidence demonstrates that impaired PD-1:PD-L function plays an important role in a variety of autoimmune diseases such as Type 1 diabetes (T1D), encephalomyelitis, inflammatory bowel diseases (IBD), Rheumatoid Arthritis (RA), autoimmune hepatitis (AIH), Behcet's disease (BD), myasthenia gravis (MG), autoimmune uveitis (AU), Sjögren's syndrome (SjS), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), myocarditis, and ankylosing spondylitis (AS). By investigating the candidate genes, genome-wide association studies, and identification of single nucleotide polymorphisms (SNPs) in PD-1 gene in humans, it has been shown that there is a higher risk in relevant genetic associations with developing autoimmune diseases in certain ethnic groups. In this review we have tried to present a comprehensive role of PD-1:PD-L in all recently studied autoimmune diseases. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmunity; PD-1; PD-L1; PD-L2

Mesh:

Substances:

Year:  2016        PMID: 27660198     DOI: 10.1016/j.cellimm.2016.09.009

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  77 in total

Review 1.  Ubiquitin Ligases in Cancer Immunotherapy - Balancing Antitumor and Autoimmunity.

Authors:  Yu Fujita; Roberto Tinoco; Yan Li; Daniela Senft; Ze'ev A Ronai
Journal:  Trends Mol Med       Date:  2019-03-18       Impact factor: 11.951

Review 2.  Inhibitory receptor agonists: the future of autoimmune disease therapeutics?

Authors:  Stephanie Grebinoski; Dario Aa Vignali
Journal:  Curr Opin Immunol       Date:  2020-06-30       Impact factor: 7.486

3.  1,25-dihydroxyvitamin D3 -induced dendritic cells suppress experimental autoimmune encephalomyelitis by increasing proportions of the regulatory lymphocytes and reducing T helper type 1 and type 17 cells.

Authors:  Zhongxiang Xie; Jingtao Chen; Chao Zheng; Jing Wu; Yun Cheng; Shan Zhu; Chenhong Lin; Qingqing Cao; Jie Zhu; Tao Jin
Journal:  Immunology       Date:  2017-07-10       Impact factor: 7.397

Review 4.  Recent advances in the clinical development of immune checkpoint blockade therapy.

Authors:  Atefeh Ghahremanloo; Arash Soltani; Seyed Mohamad Sadegh Modaresi; Seyed Isaac Hashemy
Journal:  Cell Oncol (Dordr)       Date:  2019-06-14       Impact factor: 6.730

5.  Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphoma.

Authors:  Max S Topp; Johannes Duell; Ana Maria Abajo Guijarro; Marielle Odin; Tina Nielsen; Anand Rajeswaran; Michael Wenger; Christelle Zundel; Aleksandra Bogucka-Fedorczuk; Tomasz Wrobel
Journal:  Haematologica       Date:  2020-02-06       Impact factor: 9.941

Review 6.  Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2018-04-18       Impact factor: 3.199

7.  Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition.

Authors:  Michel M Sun; Ralph D Levinson; Artur Filipowicz; Stephen Anesi; Henry J Kaplan; Wei Wang; Debra A Goldstein; Sapna Gangaputra; Robert T Swan; H Nida Sen; Lynn K Gordon
Journal:  Ocul Immunol Inflamm       Date:  2019-03-01       Impact factor: 3.070

8.  Farnesyltransferase inhibitor FTI-277 inhibits PD-L1 expression on septic spleen lymphocytes and promotes spleen lymphocyte activation.

Authors:  W Li; J Tu; X Liu; W Yang
Journal:  Clin Exp Immunol       Date:  2017-07-14       Impact factor: 4.330

Review 9.  Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.

Authors:  Justin C Kao; Adipong Brickshawana; Teerin Liewluck
Journal:  Curr Neurol Neurosci Rep       Date:  2018-08-04       Impact factor: 5.081

10.  Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma.

Authors:  Jonathan E Lu; Jessica R Chang; Jesse L Berry; Gino K In; Sandy Zhang-Nunes
Journal:  Int Ophthalmol Clin       Date:  2020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.